891 related articles for article (PubMed ID: 22632885)
21. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
Ko KS; Lee JY; Song JH; Peck KR
J Korean Med Sci; 2010 Dec; 25(12):1722-6. PubMed ID: 21165285
[TBL] [Abstract][Full Text] [Related]
22. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
Carrillo-Muñoz AJ; Quindós G; del Valle O; Santos P; Giusiano G; Ezkurra PA; Estivill MD; Casals JB
Chemotherapy; 2008; 54(1):38-42. PubMed ID: 18073469
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
Lei J; Xu J; Wang T
J Mycol Med; 2018 Jun; 28(2):310-313. PubMed ID: 29685520
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
25. Antifungal susceptibility of Candida isolates at one institution.
Katsuragi S; Sata M; Kobayashi Y; Miyoshi T; Yamashita Y; Neki R; Horiuchi C; Yamanaka K; Kamiya C; Iwanaga N; Tanaka H; Ikeda T; Yoshimatsu J
Med Mycol J; 2014; 55(1):E1-7. PubMed ID: 24682093
[TBL] [Abstract][Full Text] [Related]
26. Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984.
Lee JK; Peters D; Obias AA; Noskin GA; Peterson LR
Int J Antimicrob Agents; 2000 Nov; 16(3):205-9. PubMed ID: 11091037
[TBL] [Abstract][Full Text] [Related]
27. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
[TBL] [Abstract][Full Text] [Related]
28. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
29. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
30. Species distribution and drug susceptibilities of Candida isolates in TSARY 2010.
Yang YL; Chen HT; Lin CC; Chu WL; Lo HJ;
Diagn Microbiol Infect Dis; 2013 Jun; 76(2):182-6. PubMed ID: 23574935
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.
Pfaller MA; Hata K; Jones RN; Messer SA; Moet GJ; Castanheira M
Diagn Microbiol Infect Dis; 2011 Oct; 71(2):167-70. PubMed ID: 21696907
[TBL] [Abstract][Full Text] [Related]
32. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.
Nagappan V; Boikov D; Vazquez JA
Antimicrob Agents Chemother; 2010 Jan; 54(1):522-5. PubMed ID: 19841143
[TBL] [Abstract][Full Text] [Related]
33. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
34. Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products.
Soler L; Rodriguez JC; Belda S; Cremades R; Ruiz-Garcia M; Lopez P; Royo G
J Chemother; 2010 Aug; 22(4):283-4. PubMed ID: 20685636
[No Abstract] [Full Text] [Related]
35. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
[TBL] [Abstract][Full Text] [Related]
36. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
37. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
[TBL] [Abstract][Full Text] [Related]
38. Antifungal susceptibility profile of invasive
Memon S; Farooqi J; Zafar U; Naqvi SF; Zafar A; Jabeen K
J Med Microbiol; 2021 Dec; 70(12):. PubMed ID: 34878377
[No Abstract] [Full Text] [Related]
39. In vitro Synergistic Activity of Caspofungin Plus Polymyxin B Against Fluconazole-Resistant Candida glabrata.
Adams EK; Ashcraft DS; Pankey GA
Am J Med Sci; 2016 Mar; 351(3):265-70. PubMed ID: 26992255
[TBL] [Abstract][Full Text] [Related]
40. Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.
Sellami A; Sellami H; Néji S; Makni F; Abbes S; Cheikhrouhou F; Chelly H; Bouaziz M; Hammami B; Ben Jemaa M; Khaled S; Ayadi A
Mycopathologia; 2011 Jun; 171(6):417-22. PubMed ID: 21170738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
